CCMU
RAPT

Cheyne Capital Management (UK)’s RAPT Therapeutics RAPT Stock Holding History

Cheyne Capital Management (UK)’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,500
Closed -$332K – 20
2023
Q3 		$332K Hold
2,500
– – 0.96% 20
2023
Q2 		$374K Buy
+2,500
New +$389K 1.38% 17
2023
Q1 		– Sell
-8,979
Closed -$1.42M – 46
2022
Q4 		$1.42M Buy
+8,979
New +$1.44M 2.49% 9

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cheyne Capital Management (UK)'s RAPT Position: Q4 2023 in Review

Cheyne Capital Management (UK) sold out of RAPT Therapeutics (RAPT) in Q4 2023, closing a stake of 2,500 shares — an estimated $332K sold.

Cheyne Capital Management (UK) first reported a position in RAPT in Q4 2022 and held it in 3 quarters. The position peaked at $1.42M in Q4 2022. 108 funds tracked by Wall St. Rank hold RAPT as of Q4 2023.

  • Cheyne Capital Management (UK) reported no remaining RAPT Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 2,500 RAPT Therapeutics shares in Q4 2023, an estimated $332K.
  • Cheyne Capital Management (UK) first reported a position in RAPT Therapeutics in Q4 2022 and held it in 3 quarters.
  • Cheyne Capital Management (UK)'s RAPT Therapeutics position peaked at $1.42M in Q4 2022.
  • 108 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q4 2023, filed 12 Feb 2024.